Novo Nordisk NVO
Novo Nordisk is a Danish pharmaceutical company, global leader in diabetes and obesity treatments, with products such as Ozempic and Wegovy, generating revenue from the sale of prescription medications. Novo Nordisk maintains exceptional profitability (ROE 59.81%, operating margin 42.54%) and an attractive valuation (P/E 9.72), but the market is penalizing the sharp growth slowdown (earnings -20.6%) and dependence on its GLP-1 franchise, reflected in very negative momentum (-13.89%).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Novo Nordisk is a Danish pharmaceutical company, global leader in diabetes and obesity treatments, with products such as Ozempic and Wegovy, generating revenue from the sale of prescription medications. Novo Nordisk maintains exceptional profitability (ROE 59.81%, operating margin 42.54%) and an attractive valuation (P/E 9.72), but the market is penalizing the sharp growth slowdown (earnings -20.6%) and dependence on its GLP-1 franchise, reflected in very negative momentum (-13.89%).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.6 |
| Quality / Moat | 8.3 |
| Valuation | 6.5 |
| Growth | 2.6 |
| Dividend | 8.3 |
| Momentum | 1.4 |
| Risk & Context | 8.7 |
OVERALL SCORE: 6.6/10
Context and risks
Moderate regulatory risk in Denmark and drug pricing pressure in the US market, its main market. The -13.89% drop in momentum reflects market concerns about the slowdown in growth of its main franchise.
News considered in the analysis
- Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch — Menciona catalizadores de pipeline a corto plazo (readouts) que podrían mover la acción, pero sin detalles concretos sobre resultados.
- Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades? — Refleja la preocupación del mercado por la desaceleración del crecimiento de la franquicia GLP-1 (Wegovy/Ozempic) y la necesidad de nuevos motores de crecimiento.
- Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? — Comparativa genérica de análisis, sin información nueva sobre la empresa.
- Novo’s Pipeline Strategy Takes Another Step Forward — Indica avances en la estrategia de pipeline, un factor positivo a medio plazo para diversificar más allá de la obesidad/diabetes.
- Novo Nordisk Searches for Growth Beyond its Biggest Franchise — Subraya la dependencia de la franquicia GLP-1 y la presión para encontrar nuevas fuentes de crecimiento, un riesgo conocido y parcialmente descontado.
Verdict: Hold; quality and valuation offer support, but wait for signs that the pipeline can reaccelerate growth before adding to the position.
Main risk: The inability to find a 'second act' beyond Ozempic/Wegovy, which would lead to a prolonged growth stall and a potential further de-rating of the valuation.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →